AIRLINK 189.64 Decreased By ▼ -7.01 (-3.56%)
BOP 10.09 Decreased By ▼ -0.05 (-0.49%)
CNERGY 6.68 Decreased By ▼ -0.01 (-0.15%)
FCCL 34.14 Increased By ▲ 1.12 (3.39%)
FFL 17.09 Increased By ▲ 0.44 (2.64%)
FLYNG 23.83 Increased By ▲ 1.38 (6.15%)
HUBC 126.05 Decreased By ▼ -1.24 (-0.97%)
HUMNL 13.79 Decreased By ▼ -0.11 (-0.79%)
KEL 4.77 Increased By ▲ 0.01 (0.21%)
KOSM 6.58 Increased By ▲ 0.21 (3.3%)
MLCF 43.28 Increased By ▲ 1.06 (2.51%)
OGDC 224.96 Increased By ▲ 11.93 (5.6%)
PACE 7.38 Increased By ▲ 0.37 (5.28%)
PAEL 41.74 Increased By ▲ 0.87 (2.13%)
PIAHCLA 17.19 Increased By ▲ 0.37 (2.2%)
PIBTL 8.41 Increased By ▲ 0.12 (1.45%)
POWER 9.05 Increased By ▲ 0.23 (2.61%)
PPL 193.09 Increased By ▲ 9.52 (5.19%)
PRL 37.34 Decreased By ▼ -0.93 (-2.43%)
PTC 24.02 Decreased By ▼ -0.05 (-0.21%)
SEARL 94.54 Decreased By ▼ -0.57 (-0.6%)
SILK 0.99 Decreased By ▼ -0.01 (-1%)
SSGC 39.93 Decreased By ▼ -0.38 (-0.94%)
SYM 17.77 Decreased By ▼ -0.44 (-2.42%)
TELE 8.66 Decreased By ▼ -0.07 (-0.8%)
TPLP 12.39 Increased By ▲ 0.18 (1.47%)
TRG 62.65 Decreased By ▼ -1.71 (-2.66%)
WAVESAPP 10.28 Decreased By ▼ -0.16 (-1.53%)
WTL 1.75 Decreased By ▼ -0.04 (-2.23%)
YOUW 3.97 Decreased By ▼ -0.03 (-0.75%)
BR100 11,814 Increased By 90.4 (0.77%)
BR30 36,234 Increased By 874.6 (2.47%)
KSE100 113,247 Increased By 609 (0.54%)
KSE30 35,712 Increased By 253.6 (0.72%)

Pakistan to get COVID-19 vaccine from China to conduct clinical trials

  • State-owned China National Pharmaceutical Group, commonly known as Sinopharm, has teamed up with Karachi University’s International Centre for Chemical and Biological Sciences to hold the trials in Pakistan
Published August 14, 2020

(Karachi) Pakistan will receive coronavirus vaccine from China, one of its closest allies, to vaccinate the most vulnerable among its population, including the elderly, healthcare workers and people with medical conditions associated with serious cases of Covid-19, as per a report in the Wall Street Journal.

China has reached one of its first agreements to test its coronavirus vaccine in populations beyond its borders.

The publication stated about one-fifth of the country’s population could be covered by the allocation while Pakistan is also negotiating with another Chinese company to conduct trials of its vaccine in the country.

"China hasn’t been a major vaccine producer globally. It needs to test its COVID-19 vaccines outside its borders because coronavirus cases in China have dwindled and it is harder to find the population diversity required," read the report.

The publication reported that the state-owned China National Pharmaceutical Group, commonly known as Sinopharm, has teamed up with Karachi University’s International Centre for Chemical and Biological Sciences to hold the trials in Pakistan.

“Pakistan would get the vaccine on a priority basis,” an official involved in forging the pact told the Wall Street Journal. However, the official clarified that the financial terms of the deal are yet to be finalised.

Pakistan will conduct Phase 1 trials of the vaccine and then move rapidly to the final stage Phase 3 trial. The final phase would require tens of thousands of volunteers. China has developed three coronavirus vaccines which are in the Phase 3 trials.

Comments

Comments are closed.